# Ethics & Compliance Reviewer

## Summary
The manuscript thoroughly and appropriately addresses all ethics and compliance requirements relevant to its work. Required statements for human subject data, data governance, funding, and competing interests are clearly provided. The compliance posture is exemplary, and there are no compliance concerns.

## Strengths
- Clearly states oversight by a clinical institution's IRB and the existence of a data transfer agreement, meeting the requirement for human biospecimen research.
- Explicitly declares the absence of a funding disclosure and competing interests, fulfilling journal mandates.
- Proactively addresses data privacy and sharing restrictions, demonstrating responsible handling of sensitive clinical data.

## Weaknesses
- Load-bearing claim: The study's reproducibility and independent validation are constrained by data access. The central contribution is a computational framework evaluated on private clinical data. While the authors provide code and scripts, the core evidence (the 11-sample multimodal cohort) is stated to be under proprietary agreement and cannot be redistributed. An alternative explanation for the reported performance gains is that they are specific to the characteristics of this single, inaccessible dataset. Distinguishing between a generally robust method and one that is finely tuned to a particular private cohort requires evidence from at least one public benchmark dataset or a fully synthetic validation. The current evidence chain is incomplete for readers who cannot inspect the primary data.
- Sweep: Protocol numbers and IRB committee names are withheld for double-blind review, a standard and acceptable practice.
- Sweep: The description of patient data as "de-identified" is appropriate given the analytical context.

## Questions
- For the camera-ready version, please confirm that the anonymized ethics protocol and committee details will be restored as indicated.